- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1942
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Exposure to Infliximab During Pregnancy: Post-Marketing Experience ; volume:43 ; number:2 ; day:1 ; month:11 ; year:2019 ; pages:147-161 ; date:2.2020
Drug safety ; 43, Heft 2 (1.11.2019), 147-161, 2.2020
- Creator
-
Geldhof, Anja
Slater, Jennifer
Clark, Michael
Chandran, Urmila
Coppola, Danielle
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40264-019-00881-8
- URN
-
urn:nbn:de:101:1-2020050903281254720054
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 10:56 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Geldhof, Anja
- Slater, Jennifer
- Clark, Michael
- Chandran, Urmila
- Coppola, Danielle
- SpringerLink (Online service)
Other Objects (12)
Safety and Effectiveness of SB2 (Infliximab Biosimilar) in Adult Patients with Immune-Mediated Inflammatory Diseases: A Post-Marketing Surveillance in Korea
Real-World Safety and Effectiveness of Infliximab in 255 Patients with Intestinal, Neurological, and Vascular Behçet’s Disease: A Post-Marketing Surveillance
Pregnancy-Induced Sweet’s Syndrome Treated with Infliximab
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials
Post-marketing safety surveillance and re-evaluation of Xueshuantong injection
Post-marketing surveillance of anti-malarial medicines used in Malawi
Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
Post-marketing safety concerns with rimegepant based on a pharmacovigilance study
Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic
Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis
Safety and Effectiveness of SB2 (Infliximab Biosimilar) in Adult Patients with Immune-Mediated Inflammatory Diseases: A Post-Marketing Surveillance in Korea
Real-World Safety and Effectiveness of Infliximab in 255 Patients with Intestinal, Neurological, and Vascular Behçet’s Disease: A Post-Marketing Surveillance
Pregnancy-Induced Sweet’s Syndrome Treated with Infliximab
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials
Post-marketing safety surveillance and re-evaluation of Xueshuantong injection
Post-marketing surveillance of anti-malarial medicines used in Malawi
Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
Post-marketing safety concerns with rimegepant based on a pharmacovigilance study
Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic
Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis
Safety and Effectiveness of SB2 (Infliximab Biosimilar) in Adult Patients with Immune-Mediated Inflammatory Diseases: A Post-Marketing Surveillance in Korea
Real-World Safety and Effectiveness of Infliximab in 255 Patients with Intestinal, Neurological, and Vascular Behçet’s Disease: A Post-Marketing Surveillance
Pregnancy-Induced Sweet’s Syndrome Treated with Infliximab
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials
Post-marketing safety surveillance and re-evaluation of Xueshuantong injection
Post-marketing surveillance of anti-malarial medicines used in Malawi
Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
Post-marketing safety concerns with rimegepant based on a pharmacovigilance study
Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic